Read Larry Connors' blog – Short Term Trading Strategies
AtheroGenics Inc. (NASDAQ: AGIX | Quote | Chart | News | PowerRating) a research-based pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease. The company's V-Protectant technology based products include AGI-1067, a phase III clinical trial product for the treatment of type 2 diabetes and atherosclerosis; AGI-1096, a phase I clinical trial antioxidant and selective anti-inflammatory agent for the treatment of transplant rejection; and other V-Protectant compounds for the treatment of cardiovascular and inflammatory disease. AtheroGenics has collaboration with Astellas Pharma, Inc. to develop AGI-1096 as an oral treatment for the prevention of organ transplant rejection. The company was founded in 1993 and is based in Alpharetta, Georgia. On September 15, 2008, an involuntary petition for liquidation under Chapter 7 was filed against AtheroGenics, Inc in the US Bankruptcy Court for the Northern District of Georgia, Atlanta. On October 7, 2008, the involuntary petition was approved by the Court. With 39.52 million shares outstanding and 7.48 million shares declared short as of September 2008, there is no longer a failure to deliver in shares of AGIX. According to quarterly data provided by the SEC, there were still 12,102,225 shares of AGIX that were failing-to-deliver as of March 30, 2007.
Converted Organics Inc. Warrants (NASDAQ: COINZ) focuses on the manufacture, sale, and distribution of natural soil amendment products combining nutritional and disease suppression characteristics. It uses organic food waste as raw material to manufacture soil amendment products. Converted Organics plans to sell and distribute these products in the agribusiness, turf management, and retail markets. The company was founded in 2003 and is headquartered in Boston, Massachusetts. With 6,800 shares declared short as of September 2008, there is no longer a failure to deliver in shares of COINZ. According to quarterly data provided by the SEC, there were still 22,892 shares of COINZ that were failing-to-deliver as of February 7, 2008.
NeoMagic Corp. (NASDAQ: NMGC | Quote | Chart | News | PowerRating) designs, develops, and markets semiconductor solutions to the manufacturers of mobile phones and handheld devices. The company develops and delivers solutions for audio/video processing of the mobile digital TV standards, including ISDB-T, T-DMB, and DVB-H. It also offers a suite of middleware and sample applications for imaging, video, and audio functionality; and provides multiple operating system ports. The company's product portfolio includes semiconductor solutions known as applications processors, as well as other system-on-chips (SOCs). NeoMagic Corporation sells its applications processors under the MiMagic brand name; and SOC products under the NeoMobileTV brand name for the mobile digital TV market. It sells its products through internal sales and marketing personnel, a network of distributors, and sales representatives in the United States, Sweden, Korea, Singapore, Japan, Hong Kong, England, Malaysia, and Taiwan. The company was founded in 1993 and is headquartered in Santa Clara, California. With 12.57 million shares outstanding and 25,000 shares declared short as of September 2008, there is no longer a failure to deliver in shares of NMGC. According to quarterly data provided by the SEC, there were still 1,553,498 shares of NMGC that were failing-to-deliver as of December 15, 2004.
Opexa Therapeutics Inc. (NASDAQ: OPXA | Quote | Chart | News | PowerRating) a development stage biopharmaceutical company, develops autologous cellular therapies for the treatment of multiple sclerosis, rheumatoid arthritis, and diabetics. Its therapies are based on the company's T-cell and adult stem cell technologies. The company's products include Tovaxin, a T-cell therapeutic vaccine that is in Phase IIb clinical trial for the treatment of multiple sclerosis. Its Rheumatoid Arthritis T-cell vaccination technology, which is in preclinical development stage allows the isolation of pathogenic T-cells from synovial fluid drawn from a patient; as well as Adult Stem Cell technology that is in preclinical development stage is used to treat diabetes; and is in research and development stage to treat heart failure. The company was founded in 2003. It was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in 2006. Opexa Therapeutics is based in the Woodlands, Texas. With 12.26 million shares outstanding and 3,600 shares declared short as of September 2008, there is no longer a failure to deliver in shares of OPXA. According to quarterly data provided by the SEC, there were still 203,705 shares of OPXA that were failing-to-deliver as of February 25, 2008.
Quantum Fuel Systems Technologies Worldwide Inc. (NASDAQ: QTWW | Quote | Chart | News | PowerRating) an integrated alternative energy company, engages in the development and production of propulsion systems, energy storage technologies, and alternative fuel vehicles. Its portfolio of technologies include electronic controls, hybrid electric drive systems, hydrogen storage and metering systems, and alternative fuel technologies that enable fuel efficient, low emission hybrid, plug-in electric hybrid, fuel cell, and alternative fuel vehicles. The company also provides powertrain engineering; system integration; manufacturing and assembly of packaged fuel systems; and battery control systems for vehicles and other applications, including fuel cells, hybrids, plug-in electric hybrid, alternative fuels, and hydrogen refueling. In addition, Quantum Fuel Systems Technologies designs, engineers, and manufactures hybrid and fuel cell vehicles. The company's powertrain engineering, system integration, and assembly capabilities provide fast-to-market solutions to support the production of hybrid and plug-in hybrid, hydrogen-powered hybrid, fuel cell, alternative fuel, and specialty vehicles, as well as modular and transportable hydrogen refueling stations. Its customer base includes automotive original equipment manufacturers, military and governmental agencies, aerospace, and other strategic alliance partners. The company operates in the United States, Germany, Japan, Iceland, Hungary, and internationally. Quantum has strategic alliance with General Motors, Fisker Automotive, Asola, and Advanced Lithium Power, Inc. The company was founded in 2000 and is headquartered in Irvine, California. With 93.45 million shares outstanding and 7.55 million shares declared short as of September 2008, there is no longer a failure to deliver in shares of QTWW. According to quarterly data provided by the SEC, there were still 2,217,147 shares of QTWW that were failing-to-deliver as of July 19, 2006.
Advanced Viral Research Corp. (OTCBB: ADVR | Quote | Chart | News | PowerRating) a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions in the United States. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company develops its products focusing on the treatment of systemic symptoms, such as cachexia (body wasting), loss of appetite and lethargy experienced by patients with advanced malignant cancer, HIV-AIDS, cardiovascular disease, sepsis, viral infections, and other diseases, as well as to treat as an aid in wound healing. Its also develops its products for use as an anti-inflammatory in conditions, such as rheumatoid arthritis; and palliative agent to minimize certain toxicities associated with chemo or immunotherapies. The company was founded in 1984 and is based in Yonkers, New York. With 846.23 million shares outstanding and 913,300 shares declared short as of September 2008, there is no longer a failure to deliver in shares of ADVR. According to quarterly data provided by the SEC, there were still 8,454,142 shares of ADVR that were failing-to-deliver as of April 4, 2008.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,200,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
CONTACT: Thomas Ronk, CEO, BUYINS.NET Tel: +1 800 715 9999 e-mail: Tom@buyins.net WWW: http://www.buyins.net
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
